Lecture Series
Meeting Information From the Group
For Closed Captions, start the video and click CC at the bottom.
Blood Tests for Alzheimer's Disease - Thomas Karikari
Considerations Regarding a Diagnosis of AD Based on Biomarkers - Jetske van der Schaar
FDA Market Authorization of the Lumipulse® G β-Amyloid Ratio (1-42/1-40) Test - Rianne Esquivel
Development of Algorithm to Calculate 5 Year Absolute Risk of AD - Sarah Hartz and Jessica Mozersky
Sharing Biomarker Results with Cognitively Healthy Research Participants - Lindsay Clark
Update on Status of Blood-Based Markers for Alzheimer's Disease: Readiness for Clinical Use - Michelle M. Mielke
Biofluid Biomarkers of Neuropsychiatric Symptoms in Dementia with Lewy Bodies & Alzheimer's Disease - Fabricio Oliveira
Dementia in the Borderlands - Gladys Maestre
Aducanumab: Where do we go from here? - Josh Grill
The Next Steps Towards Precision Medicine in Parkinson's Disease - Ron Alcalay
Communicating 5 Year Risk of AD Dementia Based on Multiple Research Results to a Longitudinal Cohort of Healthy Older Adults - Jessica Mozersky
Upcoming Speakers
8/18 Barbara Bierer, Multiregional Clinical Trials (MRCT)
9/15 Nicole Fowler, U. Indiana on the Davos Collective
Previous Presentations
Anja Schneider
Topic: Germany survey of Biomarker Use in Mild Cognitive Dysfunction
